日本自體免疫疾病診斷市場：市場規模、佔有率、趨勢分析（按檢測項目、產品、檢測類型和最終用途分類）、細分市場預測（2025-2033 年）

市場規模與趨勢：

據估計，2024年日本自體免疫疾病診斷市值為3.6549億美元，預計到2033年將達到6.4045億美元，2025年至2033年的複合年成長率為6.6%。

作為全球老化速度最快的國家，日本65歲及以上人口佔比超過29%，面臨著類風濕性關節炎和自體免疫胰臟炎等疾病日益嚴重的挑戰。這推動了對抗核抗體（ANA）檢測、抗體組合和先進分子檢測的需求。此外，多重免疫測量、人工智慧和生物標記發現等領域的技術創新，以及產學研合作的加強，也為市場成長提供了支持。例如，Sysmex、MBL和Autobio Diagnostics之間的夥伴關係，提高了檢測的準確性、擴充性和早期疾病檢測能力。

根據內務部（2023年10月）的數據，日本人口為1.2435億，比前一年減少59.5萬人（-0.48%），連續第13年下降。其中男性人口為6,049萬人（-0.44%），女性人口為6,386萬人（-0.51%）。男性人口自然下降的趨勢已持續19年，女性人口自然下降的趨勢已持續15年，反映出人口持續減少的現狀。然而，淨移民趨勢以及外國居住人口的穩定成長在一定程度上抵消了人口下降的影響，日本國民淨移民數量三年來首次轉正。

這些人口趨勢直接影響自體免疫疾病診斷市場。例如，類風濕性關節炎（RA）在日本影響約82.2萬人（牛津大學出版社，2024年5月），其發病高峰年齡在65至85歲之間。由於RA在老年族群中較為常見，因此，隨著人口老化，對診斷服務的需求也隨之成長，尤其是抗核抗體（ANA）檢測、抗體組合和確證性分子檢測。

目錄

第1章：日本自體免疫疾病診斷市場：調查方法與範圍

第2章：日本自體免疫疾病診斷市場：執行摘要

• 市場概況
• 按類型和產品分類的簡介
• 按測試類型和最終用途分類的簡介
• 競爭格局概覽

第3章：日本自體免疫疾病診斷市場：影響因素、趨勢與範圍

• 市場區隔及範圍
• 市場關聯性展望
  • 母市場展望
  • 相關/附隨市場展望
• 市場動態
• 市場促進因素分析
  • 對早期、非侵入性診斷的需求日益成長
  • 技術進步
  • 產學合作
• 市場限制因素分析
  • 高昂的費用和有限的報銷
• 市場機會分析
  • 個人化醫療和基於生物標記的檢測的擴展
• 波特五力分析
• PESTLE分析

第4章：日本自體免疫疾病診斷市場：按類型分類的估算與趨勢分析

• 日本自體免疫疾病診斷市場：波動分析（按類型分類）
• 系統性自體免疫疾病診斷
  • 類風濕性關節炎
  • 僵直性脊椎炎的診斷
  • 全身性紅斑性狼瘡（SLE）
  • 其他
• 局部自體免疫疾病診斷
  • 多發性硬化症
  • 1型糖尿病
  • 橋本氏症
  • 特發性血小板減少紫斑症
  • 其他

第5章：日本自體免疫疾病診斷市場：按產品分類的估算與趨勢分析

• 日本自體免疫疾病診斷市場：波動分析（依產品分類）
• 裝置
• 耗材和檢測
• 基於質譜的分析

第6章：日本自體免疫疾病診斷市場：按檢測類型分類的估算與趨勢分析

• 日本自體免疫疾病診斷市場：按檢測類型分類的波動分析
• 抗核抗體檢測
  • 間接螢光(IIF) 抗核抗體 (ANA) 檢測
  • 基於ELISA的ANA檢測
  • 多重/多聯免疫檢測抗核抗體（ANA）檢測組
  • 其他
• 自體抗體檢測
  • 類風濕因子（RF）檢測
  • 抗環瓜氨酸肽（抗CCP）檢測
  • 抗雙股DNA檢測
  • 抗史密斯（Sm）抗體檢測
  • 抗Ro/SSA和抗La/SSB抗體檢測
  • 其他
• C反應蛋白（CRP）
• 全血球計數（CBC）
• 尿液檢查
• 其他

第7章：日本自體免疫疾病診斷市場：終端用戶估算與趨勢分析

• 日本自體免疫疾病診斷市場：依最終用途分類的波動分析
• 醫院
• 診斷中心
  • 收入估算與預測（2021-2033 年）
• 其他

第8章 競爭情勢

• 公司分類
• 策略規劃
  • 新產品上市
  • 夥伴關係
  • 企業收購
  • 商業合作
  • 資金籌措
• 主要企業市佔率分析（2024 年）
• 公司熱力圖分析
• 公司簡介
  • Fujirebio
  • SEKISUI MEDICAL CO., LTD
  • Medical &Biological Laboratories（MBL）
  • Bio-Rad Laboratories, Inc.
  • Abbott
  • F. Hoffmann-La Roche, Ltd.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • BioMerieux
  • Beckman Coulter（Danaher）

Market Size & Trends:

The Japan autoimmune disease diagnostics market size was estimated at USD 365.49 million in 2024 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world's fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.

According to the Statistics Bureau of Japan (October 2023), the country's population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.

This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.

Japan Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Systemic autoimmune disease diagnostics
  • Rheumatoid arthritis
  • Ankylosing spondylitis diagnostics
  • Systemic lupus erythematosus (SLE)
  • Others
• Localized autoimmune disease diagnostics
  • Multiple sclerosis
  • Type 1 diabetes
  • Hashimoto's Thyroiditis
  • Idiopathic thrombocytopenic purpura
  • Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables & Assays
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Antinuclear antibody tests
  • Indirect Immunofluorescence (IIF) ANA tests
  • ELISA-based ANA tests
  • Multiplex/line immunoassay ANA panels
  • Others
• Autoantibody tests
  • Rheumatoid Factor (RF) tests
  • Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
  • Anti-dsDNA tests
  • Anti-Smith (Sm) antibody tests
  • Anti-Ro/SSA & Anti-La/SSB antibody tests
  • Others
• C-reactive Protein (CRP)
• Complete blood count (CBC)
• Urinalysis
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Centers
• Others

Table of Contents

Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. End Use Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Objectives
  • 1.3.1. Objective - 1
  • 1.3.2. Objective - 2
  • 1.3.3. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Type and Product Snapshot
• 2.3. Test Type and End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising demand for early and non-invasive diagnosis
  • 3.4.2. Technological advancements
  • 3.4.3. Academic-industry collaborations
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost and limited reimbursement coverage
• 3.6. Market Opportunity Analysis
  • 3.6.1. Expansion of personalized medicine and biomarker-based testing
• 3.7. Porter's Five Forces Analysis
• 3.8. PESTLE Analysis

Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

• 4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis
• 4.2. Systemic autoimmune disease diagnostics
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Rheumatoid arthritis
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Ankylosing spondylitis diagnostics
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Systemic lupus erythematosus (SLE)
    • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.5. Others
    • 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Localized autoimmune disease diagnostics
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Multiple sclerosis
    • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Type 1 diabetes
    • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Hashimoto's Thyroiditis
    • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.5. Idiopathic thrombocytopenic purpura
    • 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.6. Others
    • 4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis

• 5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis
• 5.2. Instruments
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Consumables & Assays
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Mass spectrometry-based assays

Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

• 6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
• 6.2. Antinuclear antibody tests
  • 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.2. Indirect Immunofluorescence (IIF) ANA tests
    • 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.3. ELISA-based ANA tests
    • 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.4. Multiplex/line immunoassay ANA panels
    • 6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.2.5. Others
    • 6.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Autoantibody tests
  • 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Rheumatoid Factor (RF) tests
    • 6.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
    • 6.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Anti-dsDNA tests
    • 6.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.5. Anti-Smith (Sm) antibody tests
    • 6.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests
    • 6.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.7. Others
    • 6.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. C-reactive Protein (CRP)
  • 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Complete blood count (CBC)
  • 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Urinalysis
  • 6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Diagnostic Centers
  • 7.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. NEW PRODUCT LAUNCH
  • 8.2.2. PARTNERSHIPS
  • 8.2.3. ACQUISITION
  • 8.2.4. COLLABORATION
  • 8.2.5. FUNDING
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Fujirebio
  • 8.5.2. SEKISUI MEDICAL CO., LTD
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Medical & Biological Laboratories (MBL)
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bio-Rad Laboratories, Inc.
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Abbott
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. F. Hoffmann-La Roche, Ltd.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Siemens Healthineers AG
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Sysmex Corporation
    • 8.5.8.1. Grifols Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. BioMerieux
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Beckman Coulter ( Danaher)
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

List of Tables

• Table 1 List 0f Abbreviation
• Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
• Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 - 2033 (USD Million)
• Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
• Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market summary
• Fig. 4 Market segmentation & scope
• Fig. 5 Market size and growth prospects
• Fig. 6 Japan autoimmune disease diagnostics market - Key market driver analysis
• Fig. 7 Japan autoimmune disease diagnostics market - Key market restraint analysis
• Fig. 8 Penetration & growth prospect mapping
• Fig. 9 Japan autoimmune disease diagnostics market - Porter's analysis
• Fig. 10 Japan autoimmune disease diagnostics market - PESTEL analysis
• Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways
• Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis
• Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
• Fig. 14 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
• Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 - 2033 (USD Million)
• Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
• Fig. 17 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
• Fig. 18 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
• Fig. 19 Hashimoto's Thyroiditis market estimates, 2021 - 2033 (USD Million)
• Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
• Fig. 21 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways
• Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis
• Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
• Fig. 25 Consumables & Assays market estimates, 2021 - 2033 (USD Million)
• Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways
• Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis
• Fig. 28 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
• Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 - 2033 (USD Million)
• Fig. 30 ELISA-based ANA tests market estimates, 2021 - 2033 (USD Million)
• Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 - 2033 (USD Million)
• Fig. 32 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 33 Autoantibody tests market estimates, 2021 - 2033 (USD Million)
• Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 - 2033 (USD Million)
• Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 - 2033 (USD Million)
• Fig. 36 Anti-dsDNA tests estimates, 2021 - 2033 (USD Million)
• Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 - 2033 (USD Million)
• Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 - 2033 (USD Million)
• Fig. 39 Others estimates, 2021 - 2033 (USD Million)
• Fig. 40 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
• Fig. 41 Complete blood count (CBC) market estimates, 2021 - 2033 (USD Million)
• Fig. 42 Urinalysis market estimates, 2021 - 2033 (USD Million)
• Fig. 43 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways
• Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis
• Fig. 46 Hospitals market estimates, 2021 - 2033 (USD Million)
• Fig. 47 Diagnostic Centers market estimates, 2021 - 2033 (USD Million)
• Fig. 48 Others market estimates, 2021 - 2033 (USD Million)
• Fig. 49 Strategy framework